回复：慢性阻塞性肺疾病急性加重期是否存在点燃效应？
Reply to: Is there a kindling effect in COPD exacerbations?
作者信息
Halpin David M G, Heatley Heath, Price David
机构信息
University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK
Observational and Pragmatic Research Institute, Singapore.
出版信息
Eur Respir J. 2024 Dec 12;64(6). doi: 10.1183/13993003.02055-2024. Print 2024 Dec.
Abstract
摘要
这看起来并不是一段可翻译的文本内容，而是一个链接：https://bit.ly/3O016tT ，若要准确翻译需链接指向的具体页面文字内容。仅这个链接本身无法直接翻译为有意义的中文。
相似文献
1
Reply to: Is there a kindling effect in COPD exacerbations?回复：慢性阻塞性肺疾病急性加重期是否存在点燃效应？
Eur Respir J. 2024 Dec 12;64(6). doi: 10.1183/13993003.02055-2024. Print 2024 Dec.
2
Is there a kindling effect in COPD exacerbations?慢性阻塞性肺疾病（COPD）急性加重中是否存在点燃效应？
Eur Respir J. 2024 Dec 12;64(6). doi: 10.1183/13993003.01687-2024. Print 2024 Dec.
3
Independent effect of prior exacerbation frequency and disease severity on the risk of future exacerbations of COPD: a retrospective cohort study.既往加重频率和疾病严重程度对 COPD 未来加重风险的独立影响：一项回顾性队列研究。
NPJ Prim Care Respir Med. 2016 Sep 8;26:16046. doi: 10.1038/npjpcrm.2016.46.
4
Effect of β-blockers on the risk of COPD exacerbations according to indication of use: the Rotterdam Study.根据使用指征，β受体阻滞剂对慢性阻塞性肺疾病（COPD）急性加重风险的影响：鹿特丹研究
ERJ Open Res. 2021 Jun 28;7(2). doi: 10.1183/23120541.00624-2020. eCollection 2021 Apr.
5
Vitamin D for the management of chronic obstructive pulmonary disease.维生素D用于慢性阻塞性肺疾病的管理
Cochrane Database Syst Rev. 2024 Sep 27;9(9):CD013284. doi: 10.1002/14651858.CD013284.pub2.
6
Effect of Treatment with Mucoactive Drugs on COPD Exacerbations During 5 years of Follow-up in the Czech Republic: A Real-World Study.黏液活性药物治疗对捷克共和国5年随访期间慢性阻塞性肺疾病急性加重的影响：一项真实世界研究
Lung. 2025 May 6;203(1):61. doi: 10.1007/s00408-025-00813-7.
7
Statin Use and the Risk of Subsequent Hospitalized Exacerbations in COPD Patients with Frequent Exacerbations.他汀类药物的使用与 COPD 频繁加重患者住院加重风险的关系。
Int J Chron Obstruct Pulmon Dis. 2020 Feb 10;15:289-299. doi: 10.2147/COPD.S229047. eCollection 2020.
8
Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.布地奈德/福莫特罗干粉吸入剂对慢性阻塞性肺疾病急性加重的影响与福莫特罗相比：6 个月，随机 RISE（揭示 Symbicort 在减少 COPD 急性加重中的影响）研究。
Respir Med. 2017 Nov;132:31-41. doi: 10.1016/j.rmed.2017.09.002. Epub 2017 Sep 5.
9
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.ELOM-080对慢性支气管炎表型慢性阻塞性肺疾病患者急性加重和症状的影响——一项随机、双盲、安慰剂对照临床试验的事后分析
Int J Chron Obstruct Pulmon Dis. 2016 Nov 23;11:2877-2884. doi: 10.2147/COPD.S117652. eCollection 2016.
10
Short-Term Impact of the Frequency of COPD Exacerbations on Quality of Life.慢性阻塞性肺疾病（COPD）急性加重频率对生活质量的短期影响。
Chronic Obstr Pulm Dis. 2022 Jul 29;9(3):298-308. doi: 10.15326/jcopdf.2021.0280.
引用本文的文献
1
Differences in Blood Eosinophil Level During Stable Disease and During Exacerbation of COPD and Exacerbation Risks.慢性阻塞性肺疾病稳定期与急性加重期的血嗜酸性粒细胞水平差异及急性加重风险
Lung. 2025 Feb 27;203(1):37. doi: 10.1007/s00408-025-00792-9.
2
Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far?嗜酸性慢性阻塞性肺疾病。我们目前了解到了什么？
Pulm Ther. 2025 Mar;11(1):7-24. doi: 10.1007/s41030-024-00280-0. Epub 2024 Dec 11.
本文引用的文献
1
Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.在 COPD 诊断之前的加重病史和血嗜酸性粒细胞计数与随后的加重风险。
Eur Respir J. 2024 Oct 3;64(4). doi: 10.1183/13993003.02240-2023. Print 2024 Oct.
2
The relevance of eosinophils in chronic obstructive pulmonary disease: inflammation, microbiome, and clinical outcomes.嗜酸性粒细胞在慢性阻塞性肺疾病中的相关性：炎症、微生物组和临床结局。
J Leukoc Biol. 2024 Nov 4;116(5):927-946. doi: 10.1093/jleuko/qiae153.
3
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.全球慢性阻塞性肺疾病倡议 2023 年报告：GOLD 执行摘要。
Eur Respir J. 2023 Apr 1;61(4). doi: 10.1183/13993003.00239-2023. Print 2023 Apr.
4
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations.AERIS 研究中的肺部微生物组纵向分析表明细菌和嗜酸性 COPD 加重具有可重复性。
Thorax. 2018 May;73(5):422-430. doi: 10.1136/thoraxjnl-2017-210408. Epub 2018 Jan 31.
5
Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study.普通人群中频繁 COPD 加重者的稳定性：一项丹麦全国基于登记的研究。
NPJ Prim Care Respir Med. 2017 Apr 17;27(1):25. doi: 10.1038/s41533-017-0029-7.
6
A two-year evaluation of the 'real life' impact of COPD on patients in Germany: The DACCORD observational study.德国慢性阻塞性肺疾病（COPD）对患者“现实生活”影响的两年评估：DACCORD观察性研究
Respir Med. 2017 Mar;124:57-64. doi: 10.1016/j.rmed.2017.02.007. Epub 2017 Feb 16.
Zotero 插件